drugset / Trial / NCT01629368

A Study of the Effect of Carbamazepine on the Pharmacokinetics of RO4917523 in Healthy Volunteers

NCT01629368

Phase 1 Completed 16 enrolled Hoffmann-La Roche
Non-randomizedCrossoverOpen-label

Summary

This single-center, open-label, cross-over study will evaluate the effect of carbamazepine on the pharmacokinetics of RO4917523 in healthy volunteers. Healthy volunteers will receive a single dose of RO4917523 alone and in combination with multiple doses of carbamazepine in a cross-over design. The anticipated time on study treatment is 40 days.

Timeline

Start
2012-06
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Basimglurant Small molecule
Subject Carbamazepine Small molecule

Indications

No indication recorded.